SCHEMBL4013900

SCHEMBL4013900

CC(=O)OC[C@H]1O[C@@H](n2cc(NC(=O)OC(C)(C)C)c3c(Cl)ncnc32)[C@](C)(OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ ADK P55263 1/20 0.31
▸ XDH P47989 1/20 0.30
▸ PRKAB2 O43741 1/20 0.30
▸ PRKAG1 P54619 1/20 0.30
▸ PRKAA2 P54646 1/20 0.30
▸ PRKAA1 Q13131 1/20 0.30
▸ PRKAG3 Q9UGI9 1/20 0.30
▸ PRKAG2 Q9UGJ0 1/20 0.30
▸ PRKAB1 Q9Y478 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020234 0.91 ABL1 (0.36) ADK
SCHEMBL4013424 0.90 XDH (0.32) XDHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL13650031 0.81 — —
SCHEMBL16496977 0.81 RET (0.36) ADK
SCHEMBL13598728 0.81 ALDH1A1 (0.35) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL4020271 0.81 ALDH1A1 (0.35) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL13650035 0.80 — —
SCHEMBL13494177 0.79 XDH (0.34) LMNAXDHPRKAB2PRKAG1PRKAA2
SCHEMBL4011551 0.77 ALDH1A1 (0.38) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL13598729 0.77 ALDH1A1 (0.38) ALDH1A1LMNATP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253648-A1 Tricyclic-Nucleoside Compounds for Treating Viral Infections SMITHKLINE BEECHAM CORPORATION (US) 2009-10-08 — — US disclosed
US-7524825-B2 Tricyclic-nucleoside compounds for treating viral infections SMITHKLINE BEECHAM CORPORATION (US) 2009-04-28 — — US disclosed
US-20090048189-A1 TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. 2009-02-19 — — US disclosed
US-20060252715-A1 Tricyclic-nucleoside compounds for treating viral infections GENELABS TECHNOLOGIES, INC. 2006-11-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048189-A1 TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS TYMP, PNP, NSUN2 ALDH1A1 1283/4885LMNA 1445/4885TP53 3130/4885
US-20060252715-A1 Tricyclic-nucleoside compounds for treating viral infections PNP, TYMP, NSUN2 ALDH1A1 1780/4885LMNA 974/4885TP53 2790/4885
US-20090253648-A1 Tricyclic-Nucleoside Compounds for Treating Viral Infections PNP, TYMP, NSUN2 ALDH1A1 1780/4885LMNA 974/4885TP53 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback